Takhzyro denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Takhzyro Quantity — and Why You Can Appeal

Quantity-limit denials for Takhzyro (lanadelumab) usually arise because UHC's system restricts the number of injections dispensed per fill or per time period to correspond to the FDA-approved dosing schedule. If the prescription as written was interpreted as exceeding that schedule, or if a refill was requested before the plan's dispensing interval expired, the claim is automatically denied.

This is often an administrative mismatch between the prescription format and the plan's coverage parameters — not a judgment that the drug is inappropriate for you. Correcting the prescription format or providing prescriber documentation that the order matches the approved label frequently resolves the denial.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 guarantee internal appeal and independent external review rights.
• Internal appeal deadline: 180 days from the denial notice.
• External review window: approximately 4 months after final internal denial.
• Expedited review is available if delay poses a health risk — relevant for patients with frequent severe HAE attacks.

## Appeal Timeline

1. Request the denial letter and the quantity-limit specification in UHC's coverage policy. 2. Compare the prescribed quantity and interval against the FDA-approved prescribing information. 3. If the prescription matches the label, resubmit with a prescriber attestation; if the plan's system is wrong, the appeal will address that. 4. File a formal internal appeal if resubmission is denied. 5. Escalate to external IRO if the internal appeal is denied.

## Documentation to Gather

• FDA label alignment: Current Takhzyro prescribing information from DailyMed showing the approved dosing schedule; prescriber letter confirming the prescribed quantity matches this exactly.
• Diagnosis confirmation: Lab or genetic confirmation of HAE.
• Clinical need for approved quantity: If your prescriber is ordering the quantity at the frequency stated in the FDA label, this is the core of your argument — document it explicitly.
• Attack history: If there is any clinical argument for the dosing interval selected, provide supporting attack-frequency data from the chart.
• Refill timing documentation: If the denial is timing-based (early refill), provide documentation of medical necessity for the refill (e.g., supply was lost, dosing change was authorized).

## Criteria-Mapping Structure

| Quantity-Limit Policy Requirement | Documentation Response | |---|---| | Quantity per fill does not exceed label-approved amount | FDA prescribing information + prescriber attestation | | Refill interval meets plan requirement | Dispensing history and prescriber order | | Medical necessity for any exception quantity | Chart documentation if seeking above-standard quantity |

Verify the exact approved dosing schedule in the current FDA prescribing information at DailyMed before submitting your appeal. Use that language verbatim in your prescriber's attestation letter.